About the Study: Among patients with acute ischemic stroke treated within 48 hours of symptom onset, intravenous loberamisal, compared with placebo, resulted in a higher proportion of patients achieving full functional outcomes at 90 days. Further studies are needed to validate these findings and establish whether the benefits could extend to a broader patient population.
Meeting Information: This paper will be presented at the 29th National Conference on Neurology in Xi’an, China.
Related: This paper has an Editorial.
Corresponding Authors: Yongjun Wang, MD (yongjunwang@ncrcnd.org.cn), and Shuya Li, MD (shuyali85@163.comli85@163.com), Department of Neurology, Beijing Tiantan Hospital, No. 119 S Fourth Ring W Rd, Fengtai District, Beijing 100070, China.
10.1001/jama.2026.16557
To access the embargoed study: Visit our JAMA Network Media Center at this link https://media.jamanetwork.com/
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Editor's Note: Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Journal
JAMA